InMode, the Israeli energy-device manufacturer known for its fractional RF microneedling (Morpheus8) and radiofrequency platforms, received an unsolicited takeover proposal. While the bidder's identity and offer terms remain undisclosed, the move signals intensifying consolidation pressure in the aesthetic device market as larger players and PE firms seek to consolidate fragmented RF and laser portfolios.
Business & M&A
InMode Receives Unsolicited Takeover Offer — Consolidation Pressure Mounts in Energy-Device Space
PE or strategic buyer circles InMode; device M&A cycle accelerates.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
InMode targeted in unsolicited bid; Morpheus8 users should monitor post-acquisition terms.
For practice owners, InMode's potential acquisition could reshape device financing, support infrastructure, and product roadmap. Morpheus8 has gained significant market share in RF microneedling, competing directly with Cutera's Evolve and Lumenis platforms. A change in ownership could affect pricing, lease terms, clinical training, and software updates. Practices should monitor the deal outcome and any post-acquisition changes to service agreements or upgrade costs. Consolidation often leads to price increases and reduced flexibility in device terms.
Source: original report ↗
Frequently asked questions
What happens to Morpheus8 if InMode gets acquired?
If acquired, Morpheus8 pricing, lease terms, clinical training, and software updates could all change under new ownership. Consolidation in the device market typically results in price increases and reduced flexibility in device financing and service agreements, so practices should lock in favorable terms now if possible.
Will InMode acquisition affect my practice's device lease costs?
Yes, consolidation often leads to higher pricing and stricter lease terms. Practices should review their current InMode contracts and consider renegotiating before any acquisition closes, as post-acquisition owners typically increase costs and reduce negotiating power for existing customers.
Why is InMode being targeted for acquisition?
InMode's Morpheus8 fractional RF microneedling platform has captured significant market share and competes directly with Cutera's Evolve and Lumenis platforms. Larger strategic buyers and PE firms are consolidating fragmented RF and laser portfolios to gain scale and pricing power in the energy-device market.
Should I switch from Morpheus8 to another RF microneedling device?
Not necessarily immediately, but you should monitor the deal outcome and compare terms with competing platforms like Cutera Evolve or Lumenis before any acquisition closes. Lock in favorable pricing and support agreements with your current vendor now if you plan to stay, or evaluate alternatives while you still have leverage.
What other aesthetic device companies are at risk of acquisition?
The energy-device space is experiencing accelerated M&A activity as larger players consolidate fragmented RF and laser portfolios. Any mid-sized manufacturer with strong market share in RF, laser, or microneedling technology could be a target, making it a good time for practices to audit their device vendor concentration risk.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.